+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2026-2032- Product Image
Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2026-2032- Product Image
Sale

Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6081619
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Treating Chronic Myeloid Leukemia by Phase Market is projected to reach USD 5.26 Billion in 2026. It is expected to continue growing at a CAGR of 7.33%, reaching USD 8.08 Billion by 2032.

Chronic Myeloid Leukemia Treatment by Disease Phase

Chronic myeloid leukemia (CML) treatment is organized around disease phase, molecular response, patient tolerance, and the risk of progression. Clinical management commonly distinguishes chronic, accelerated, and blast phases, with treatment intensity increasing when disease control is inadequate or transformation occurs. Tyrosine kinase inhibitors (TKIs) remain central to care, while monitoring of BCR::ABL1 transcript levels guides response assessment and treatment decisions.

Phase-Specific Care Is Becoming More Response-Driven

CML care has shifted from a largely uniform treatment model toward response-adapted management. In chronic phase, clinicians typically prioritize durable molecular control and long-term tolerability. In accelerated or blast phase, treatment planning may involve more intensive combinations, evaluation for allogeneic stem-cell transplantation, and management of complications associated with advanced disease. Treatment selection is increasingly influenced by prior TKI exposure, resistance mutations, comorbidities, adherence, and patient preferences regarding long-term therapy or treatment-free remission.

Artificial Intelligence Strengthens Monitoring and Decision Support

Artificial intelligence can support CML management by improving interpretation of longitudinal laboratory data, identifying patients at risk of inadequate response, and helping clinicians recognize patterns associated with intolerance or progression. Potential applications include automated review of BCR::ABL1 trends, adherence-risk detection, and integration of molecular, clinical, and treatment-history data. These tools remain dependent on high-quality datasets, transparent validation, clinical oversight, and safeguards against biased recommendations; they complement rather than replace hematologist judgment.

Regional Differences Reflect Access, Diagnostics, and Specialist Capacity

North America generally benefits from established molecular monitoring and access to multiple TKI options, although affordability and continuity of care remain important concerns. Europe combines sophisticated guideline-based care with variation in reimbursement and availability across countries. Asia-Pacific includes highly advanced systems alongside settings where molecular testing and specialist access are uneven. Latin America faces disparities in diagnostic infrastructure, treatment financing, and follow-up. In the Middle East, specialized centers coexist with variable referral pathways and access. Africa continues to encounter substantial challenges involving diagnosis, treatment availability, molecular monitoring, and specialist capacity.

International Groupings Reveal Uneven Health-System Readiness

Across ASEAN, CML care varies with national insurance coverage, laboratory capacity, and access to hematology expertise. BRICS members show wide differences in diagnostic infrastructure, medicine procurement, and availability of transplantation services. The European Union benefits from shared clinical standards but retains country-level variation in reimbursement and implementation. G7 systems generally have strong specialist capacity and molecular monitoring, while affordability and health-equity issues persist. GCC countries often have concentrated advanced-care capacity, with referral and workforce needs differing by state. NATO membership does not imply uniform CML services; participating health systems remain diverse in access, procurement, and clinical infrastructure.

Country-Level Priorities Span Access, Monitoring, and Advanced Care

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally possess mature specialist-care capabilities, though reimbursement, regional access, and treatment continuity differ. China and India are expanding diagnostic and oncology capacity while addressing geographic and affordability disparities. Brazil, Mexico, and Russia face varied access conditions across public and private systems, including differences in molecular monitoring and specialist availability. Across all listed countries, durable outcomes depend on timely diagnosis, reliable BCR::ABL1 testing, adherence support, resistance assessment, and referral pathways for advanced disease and transplantation.

Prioritize Response Monitoring, Equitable Access, and Patient-Centered Sequencing

Industry leaders should strengthen access to standardized molecular testing, establish clear escalation pathways for inadequate response, and embed adherence and adverse-event support into routine care. Treatment strategies should account for comorbidities, resistance biology, pregnancy considerations, drug interactions, and patient preferences. Health systems can improve continuity through shared-care models, telehematology, reliable medicine supply, and patient navigation. Developers and care providers should validate digital and AI tools prospectively, document clinical utility, protect patient data, and ensure that innovation supports-not widens-regional and socioeconomic differences in care.

Methodology for a Phase-Based Executive Assessment

This executive summary uses a clinical and health-system framework for CML treatment by disease phase. It synthesizes established principles of phase classification, molecular response monitoring, TKI sequencing, resistance management, transplantation referral, and supportive care, then organizes implications across the specified regions, international groups, and countries. The assessment is qualitative and intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific analysis. Findings should be interpreted alongside current clinical guidelines, regulatory requirements, local reimbursement policies, and country-level epidemiology.

Phase-Specific Precision Is the Core Direction of CML Care

CML management increasingly depends on matching treatment intensity and monitoring frequency to disease phase, molecular response, resistance risk, and patient circumstances. Strong outcomes require more than access to medicines: they depend on timely diagnosis, dependable molecular testing, adherence support, specialist expertise, and coordinated escalation for advanced disease. Regional and country differences make implementation especially important, while responsible use of artificial intelligence may improve consistency and early risk recognition when supported by robust evidence and clinical governance.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Type
7.1. Introduction
7.2. Chemotherapy
7.3. Stem Cell Transplantation
7.4. Tyrosine Kinase Inhibitor
7.4.1. First Generation TKI
7.4.2. Second Generation TKI
7.4.2.1. Bosutinib
7.4.2.2. Dasatinib
7.4.2.3. Nilotinib
7.4.3. Third Generation TKI
8. Treating Chronic Myeloid Leukemia by Phase Market, by Phase
8.1. Introduction
8.2. Accelerated Phase
8.3. Blast Crisis
8.4. Chronic Phase
9. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Setting
9.1. Introduction
9.2. Hospital Inpatient
9.3. Hospital Outpatient
9.4. Specialty Clinic
10. Treating Chronic Myeloid Leukemia by Phase Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Treating Chronic Myeloid Leukemia by Phase Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Treating Chronic Myeloid Leukemia by Phase Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Treating Chronic Myeloid Leukemia by Phase Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. AstraZeneca PLC
15.3. Biogen Inc.
15.4. Bristol-Myers Squibb Company
15.5. Celgene Corporation by Bristol Myers Squibb Company
15.6. Cipla Limited
15.7. Dr. Reddy’s Laboratories Limited
15.8. Eisai Co., Ltd.
15.9. F. Hoffmann-La Roche Ltd.
15.10. Gilead Sciences, Inc.
15.11. GlaxoSmithKline PLC
15.12. Incyte Corporation
15.13. Intas Pharmaceuticals Limited
15.14. Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
15.15. Merck KGaA
15.16. Novartis AG
15.17. Pfizer Inc.
15.18. Sun Pharmaceutical Industries Limited
15.19. Takeda Pharmaceutical Company Limited
15.20. Teva Pharmaceutical Industries Limited
15.21. Viatris Inc.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Treating Chronic Myeloid Leukemia by Phase Market, Years Considered for the Study
FIGURE 2. Global Treating Chronic Myeloid Leukemia by Phase Market, Research Design
FIGURE 3. Global Treating Chronic Myeloid Leukemia by Phase Market, Research Framework
FIGURE 4. Global Treating Chronic Myeloid Leukemia by Phase Market, Data Triangulation
FIGURE 5. Global Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2025 vs 2032 (%)
FIGURE 9. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2025 vs 2032 (%)
FIGURE 11. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Treating Chronic Myeloid Leukemia by Phase Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Treating Chronic Myeloid Leukemia by Phase Market Segmentation & Coverage
TABLE 2. Global Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 3. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Chemotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Chemotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Chemotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Stem Cell Transplantation Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Stem Cell Transplantation Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Stem Cell Transplantation Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Tyrosine Kinase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Tyrosine Kinase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Tyrosine Kinase Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global First Generation TKI Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global First Generation TKI Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global First Generation TKI Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Second Generation TKI Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Second Generation TKI Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Second Generation TKI Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Bosutinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Bosutinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Bosutinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Dasatinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Dasatinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Dasatinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Nilotinib Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Nilotinib Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Nilotinib Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Third Generation TKI Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Third Generation TKI Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Third Generation TKI Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 32. Global Accelerated Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Accelerated Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Accelerated Phase Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Blast Crisis Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Blast Crisis Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Blast Crisis Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Chronic Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Chronic Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Chronic Phase Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 42. Global Hospital Inpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Hospital Inpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Hospital Inpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Hospital Outpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Hospital Outpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Hospital Outpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 52. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 69. North America Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. North America Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 71. North America Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 72. North America Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 73. North America Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 74. North America Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 75. North America Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 76. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 78. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 79. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 80. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 81. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 82. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 83. Europe Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Europe Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 85. Europe Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 86. Europe Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 87. Europe Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 88. Europe Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 89. Europe Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 90. Middle East Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Middle East Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 92. Middle East Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 93. Middle East Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 94. Middle East Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 95. Middle East Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 96. Middle East Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 97. Africa Treating Chronic Myeloid Leukemia by Phase Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Africa Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 99. Africa Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 100. Africa Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 101. Africa Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 102. Africa Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 103. Africa Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 104. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. ASEAN Treating Chronic Myeloid Leukemia by Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 106. ASEAN Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 107. ASEAN Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 108. ASEAN Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 109. ASEAN Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 110. ASEAN Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 111. ASEAN Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 112. GCC Treating Chronic Myeloid Leukemia by Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. GCC Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 114. GCC Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 115. GCC Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 116. GCC Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 117. GCC Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 118. GCC Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 119. European Union Treating Chronic Myeloid Leukemia by Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. European Union Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 121. European Union Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 122. European Union Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 123. European Union Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 124. European Union Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 125. European Union Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 126. BRICS Treating Chronic Myeloid Leukemia by Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. BRICS Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 128. BRICS Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 129. BRICS Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 130. BRICS Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 131. BRICS Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 132. BRICS Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 133. G7 Treating Chronic Myeloid Leukemia by Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 134. G7 Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 135. G7 Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 136. G7 Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 137. G7 Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 138. G7 Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 139. G7 Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 140. NATO Treating Chronic Myeloid Leukemia by Phase Market Size, by Group, 2017-2032 (USD Million)
TABLE 141. NATO Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 142. NATO Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 143. NATO Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 144. NATO Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 145. NATO Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 146. NATO Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 147. Global Treating Chronic Myeloid Leukemia by Phase Market Size, by Country, 2017-2032 (USD Million)
TABLE 148. United States Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 149. United States Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 150. United States Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 151. United States Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 152. United States Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 153. United States Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 154. United States Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 155. Canada Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 156. Canada Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 157. Canada Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 158. Canada Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 159. Canada Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 160. Canada Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 161. Canada Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 162. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 163. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 164. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 165. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 166. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 167. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 168. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 169. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 170. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 171. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 172. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 173. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 174. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 175. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 176. United Kingdom Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 177. United Kingdom Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 178. United Kingdom Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 179. United Kingdom Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 180. United Kingdom Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 181. United Kingdom Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 182. United Kingdom Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 183. Germany Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 184. Germany Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 185. Germany Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 186. Germany Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 187. Germany Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 188. Germany Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 189. Germany Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 190. France Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 191. France Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 192. France Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 193. France Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 194. France Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 195. France Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 196. France Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 197. Russia Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 198. Russia Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 199. Russia Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 200. Russia Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 201. Russia Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 202. Russia Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 203. Russia Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 204. Italy Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 205. Italy Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 206. Italy Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 207. Italy Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 208. Italy Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 209. Italy Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 210. Italy Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 211. Spain Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 212. Spain Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 213. Spain Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 214. Spain Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 215. Spain Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 216. Spain Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 217. Spain Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 218. China Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 219. China Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 220. China Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 221. China Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 222. China Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 223. China Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 224. China Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 225. India Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 226. India Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 227. India Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 228. India Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 229. India Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 230. India Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 231. India Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 232. Japan Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 233. Japan Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 234. Japan Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 235. Japan Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 236. Japan Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 237. Japan Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 238. Japan Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 239. Australia Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 240. Australia Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 241. Australia Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 242. Australia Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 243. Australia Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 244. Australia Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 245. Australia Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 246. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size, 2017-2032 (USD Million)
TABLE 247. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 248. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size, by Tyrosine Kinase Inhibitor, 2017-2032 (USD Million)
TABLE 249. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size, by Second Generation TKI, 2017-2032 (USD Million)
TABLE 250. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size, by Phase, 2017-2032 (USD Million)
TABLE 251. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size, by Treatment Setting, 2017-2032 (USD Million)
TABLE 252. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 253. Global Treating Chronic Myeloid Leukemia by Phase Market Share, by Key Player, 2025
TABLE 254. Global Treating Chronic Myeloid Leukemia by Phase Market, Key Experts

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation by Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Intas Pharmaceuticals Limited
  • Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.

Related Topics

Related Reports

TKI for Chronic Myeloid Leukemia Market - Global Forecast 2026-2032 - Product Image

TKI for Chronic Myeloid Leukemia Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Leukemia Therapeutics Market - Global Forecast 2026-2032 - Product Image

Leukemia Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Acute Myeloid Leukemia Market Report 2026 - Product Image

Acute Myeloid Leukemia Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Acute Lymphocytic Leukemia - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Acute Lymphocytic Leukemia - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 257 Pages
  • Global
From
Acute Myeloid Leukemia - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Acute Myeloid Leukemia - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.